Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 11, 2022 20:40 ET | Source: Mesoblast Limited

Rexlemestrocel-L to be Highlighted at Maxim’s Panel on Late-Stage Advancements in Heart Failure Therapeutics and Management

NEW YORK, July 11, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that rexlemestrocel-L,...
June 09, 2022 07:00 ET | Source: Mesoblast Limited

Mesoblast Key Opinion Leader Event Series for Investors & Analysts

NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webinar focused on the...
May 31, 2022 20:15 ET | Source: Mesoblast Limited

Operational Highlights and Financial Results for the Period Ended March 31, 2022

NEW YORK, May 31, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) global leader in allogeneic cellular medicines for inflammatory diseases, today reported financial results and...
April 28, 2022 20:35 ET | Source: Mesoblast Limited

Appendix 4C Quarterly Activity Report

NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for...
March 23, 2022 20:40 ET | Source: Mesoblast Limited

Philip R. Krause, M.D., Former FDA Deputy Chief for Vaccines, Joins Mesoblast Board

NEW YORK, March 23, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that Philip R....
February 24, 2022 17:30 ET | Source: Mesoblast Limited

Operational Highlights and Financial Results for the Period Ended December 31, 2021

NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported financial results and...
February 24, 2022 05:57 ET | Source: Mesoblast Limited

Mesoblast Corporate Update and Financial Results Webcast

NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss...
February 20, 2022 18:19 ET | Source: Mesoblast Limited

Rapid Improvement and Remission in Patients With Refractory Ulcerative Colitis and Crohn’s Colitis After Direct Injection of Remestemcel-L by Colonoscopy

NEW YORK, Feb. 20, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced positive results from...
February 01, 2022 19:20 ET | Source: Mesoblast Limited

Mesoblast Appoints Dr. Eric Rose as Chief Medical Officer

NEW YORK, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, is pleased to announce the appointment...
January 30, 2022 19:16 ET | Source: Mesoblast Limited

Appendix 4C Quarterly Activity Report

NEW YORK, Jan. 30, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an operational and...